It is believed the lenacapavir shot could end HIV/Aids in the country within 14 to 18 years if enough people were to take it.

Researchers at La Jolla Institute for Immunology, Scripps Research, and the Ragon Institute of MGH, MIT, and Harvard report coordinated studies showing that several HIV germline-targeting immunogens ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...